The 5th China International Import Expo (CIIE) saw the announcement of a partnership between US-based Pfizer (NYSE: PFE), the Chinese Alliance for Rare Disease (CARD), China Social Assistance Foundation (CSAF), and Ping An Healthcare and Technology Co., Ltd (HKG: 1833), also known as PingAn Good Doctor. The collaboration aims to enhance hemophilia management in China through a series of measures, including multi-tiered treatment security, a one-stop management platform, digital high-efficiency physician and patient education, systemic skill training, and more.
Current Hemophilia Treatment Landscape
Currently, only 16% of hemophilia patients in China receive prevention and treatment, significantly lower than the global rate of 60%. This partnership will focus on integrating the entire chain of comprehensive hemophilia management through a technical platform and promoting the construction of hemophilia centers. The initiative will also actively promote the hemophilia prevention system and “promote construction with evaluation” to build a 6C (Care) comprehensive care patient management service encompassing “medicine + diagnosis and treatment + payment + nursing + psychology + patient education.”
Future Development and Rare Disease Focus
Additionally, Pfizer is developing a rare disease gene therapy to further advance the diagnosis and treatment of rare diseases in China and globally. This strategic move underscores Pfizer’s commitment to improving the management and treatment of rare diseases, particularly hemophilia, and enhancing patient outcomes through comprehensive care initiatives.-Fineline Info & Tech
